← Back to Clinical Trials
Recruiting NCT07106593

NCT07106593 Treatment for PTSD and Tinnitus

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07106593
Status Recruiting
Phase
Sponsor The University of Texas Health Science Center at San Antonio
Condition PTSD - Post Traumatic Stress Disorder
Study Type INTERVENTIONAL
Enrollment 160 participants
Start Date 2025-08-08
Primary Completion 2028-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Cognitive Processing TherapyCBT-t

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 160 participants in total. It began in 2025-08-08 with a primary completion date of 2028-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In this study, researchers are examining the best sequence of interventions for posttraumatic stress disorder (PTSD) and tinnitus. Participants will either receive psychotherapy for PTSD first (Cognitive Processing Therapy; CPT), followed by treatment for tinnitus (Cognitive Behavioral Therapy for Tinnitus; CBT-t); or vice-versa. We also aim to identify changes in brain functioning after receiving therapy.

Eligibility Criteria

Inclusion Criteria: * Adult male and female active duty military personnel and veterans seeking treatment for PTSD * Diagnosis of PTSD * Person has experienced at least one mild traumatic brain injury (concussion) * Ability to speak and read English * Stable on any psychotropic medications * Meets criteria for chronic subjective and bothersome tinnitus * Chronic tinnitus is at least possibly related to head injury Exclusion Criteria: * Currently receiving other talk therapies * Severe hearing loss that would prevent the participant from benefiting from therapy * Current severe suicidal ideation * Psychiatric hospitalization in the last 12 months * Moderate to severe substance use that would prevent the participant form benefiting from therapy * Current manic episode or psychotic symptoms requiring immediate stabilization or hospitalization * Significant cognitive impairment * Moderate to severe brain damage * Neurobiological disorders * Temporomandibular joint disorders and/or Meniere's disease that cause acute pain

Contact & Investigator

Central Contact

Amanda Flores, BA

✉ floresa13@uthscsa.edu

📞 210-562-6726

Principal Investigator

John Moring, PhD

PRINCIPAL INVESTIGATOR

The University of Texas Health Science Center at San Antonio

Frequently Asked Questions

Who can join the NCT07106593 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying PTSD - Post Traumatic Stress Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07106593 currently recruiting?

Yes, NCT07106593 is actively recruiting participants. Contact the research team at floresa13@uthscsa.edu for enrollment information.

Where is the NCT07106593 trial being conducted?

This trial is being conducted at San Antonio, United States.

Who is sponsoring the NCT07106593 clinical trial?

NCT07106593 is sponsored by The University of Texas Health Science Center at San Antonio. The principal investigator is John Moring, PhD at The University of Texas Health Science Center at San Antonio. The trial plans to enroll 160 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology